| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3999702 | Urologic Oncology: Seminars and Original Investigations | 2015 | 6 Pages |
Abstract
PSAHL estimated at the first follow-up visit is an independent prognostic factor for newly diagnosed mPCa. If the prospective validation test is performed on a large scale, it may demonstrate that PSAHL is an early surrogate prognostic factor of newly diagnosed mPCa.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
Ki Hong M.D., Kyung Seok M.D., Ph.D., Kwang Hyun M.D., Ph.D., Dae Keun M.D., Kyo Chul M.D., Ph.D., Koon Ho M.D., Ph.D., Young Deuk M.D., Ph.D., Sung Joon M.D., Ph.D.,